课题基金 / 基金详情

项目摘要

项目成果

Henry J. Pownall的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 人血浆高密度脂蛋白(HDL)是胆固醇逆向转运的主要载体,是血清不透明因子(SOF)的靶点,SOF是化脓性链球菌的毒力决定因子,可使血清不透明。HDL包括中性脂质、胆固醇酯和一些甘油三酯的核心,被胆固醇、磷脂和专门蛋白质[载脂蛋白(apo)A-I和A-II]的表面单层包围。HDL是存在于动力学陷阱中的不稳定颗粒,其可以通过离液序列高、去污剂或热扰动从动力学陷阱中逃逸。重组(r)SOF催化几乎所有中性脂质的转移?100,000 HDL颗粒(D?8.5 nm)进入单一的、大的富含胆固醇酯的微乳液(CERM; D > 100 nm),留下新的HDL样颗粒[neo HDL(D?5.8 nm)],同时释放无脂质(LF)apo A-I。CERM形成和apo A-I释放具有相似的动力学,表明平行或快速连续步骤。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Human plasma high-density lipoproteins (HDL), the primary vehicle for reverse cholesterol transport, are the target of serum opacity factor (SOF), a virulence determinant of Streptococcus pyogenes that turns serum opaque. HDL comprises a core of neutral lipids, cholesteryl esters and some triglycerides, surrounded by a surface monolayer of cholesterol, phospholipids, and specialized proteins [apolipoproteins (apos) A-I and A-II]. A HDL is an unstable particle residing in a kinetic trap from which it can escape via chaotropic, detergent, or thermal perturbation. Recombinant (r) SOF catalyzes the transfer of nearly all neutral lipids of ?100,000 HDL particles (D ? 8.5 nm) into a single, large cholesteryl ester-rich microemulsion (CERM; D > 100 nm), leaving a new HDL-like particle [neo HDL (D ? 5.8 nm)] while releasing lipid-free (LF) apo A-I. CERM formation and apo A-I release have similar kinetics, suggesting parallel or rapid consecutive steps.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Atheroprotection via Reduced Plasma High Density Lipoprotein-Free Cholesterol Bioavailability
Atheroprotection via Reduced Plasma High Density Lipoprotein-Free Cholesterol Bioavailability
Atheroprotection via Reduced Plasma High Density Lipoprotein-Free Cholesterol Bioavailability
High Density Lipoprotein Biogenesis and Speciation
海外基金